Category Archives: Drugs

FDA approved psychoactive medication for Children

Fluoxetine for Pediatric Patients US FDA Approved for Pediatric Use Major depressive disorder (fluoxetine, ages 8 and older) Obsessive compulsive disorder (fluoxetine, ages 7 and older) Bipolar depression [in combination with olanzapine (Symbyax), ages 10 and older] Off-Label for Pediatric Use But Approved in Adults Panic disorder (fluoxetine, fluoxetine weekly) Premenstrual dysphoric disorder (Sarafem) Bulimia […]

TOPIRAMATE

Topiramate What’s of Interest: In 2014, Topamax (topiramate) became the first medication approved to prevent migraine headaches in adolescents (ages 12 to 17) Brands Topamax, others Class Anticonvulsant, voltage-sensitive sodium channel modulator Approved For: Migraine prophylaxis (ages 12 and older)  Other indications include partial onset seizures, primary generalized tonic-clonic seizures, seizures associated with Lennox-Gastaut Syndrome, and chronic […]

OLANZAPINE

Olanzapine What’s of Interest: US FDA warned that olanzapine is associated with a rare but serious skin condition known as Drug Reaction with Eosinophilia (DRESS). DRESS may begin as a rash but can progress to others parts of the body and can include symptoms such as fever, swollen lymph nodes, swollen face, inflammation of organs, […]

CLOZAPINE

Clozapine What’s of Interest: Clozapine REMS and ANC monitoring update Brands Clozaril, Leponex, Versacloz (oral suspension), Fazaclo ODT (oral disintegrating tablet) Class Atypical antipsychotic (serotonin-dopamine antagonist; second-generation antipsychotic; also a mood stabilizer) Approved For: Treatment-resistant schizophrenia   Reduction in risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder     Formulation: Tablet […]

May 21, 2018   :FDA Approves First Non-Opioid to Treat Opioid Withdrawal Symptoms 

    The US FDA has approved the first non-opioid treatment for the relief of opioid withdrawal symptoms. The medication, lofexidine hydrochloride (trade name Lucemyra), is an oral, selective alpha-2 adrenergic receptor agonist that reduces the release of norepinephrine, which may lead to relief of autonomic withdrawal symptoms. Loxefidine is not approved for the treatment […]